PURPOSE: The purpose of this Phase II multi-institutional study was to define the efficacy and toxicity of ixabepilone in patients with advance pancreatic adenocarcinoma. PATIENTS AND METHODS: Patients were required to have pancreatic adenocarcinoma and metastatic or recurrent disease that was not amenable to curative resection. Performance status was 0-1, and patients could not have had prior chemotherapy, or chemoradiation therapy for their advanced disease although prior local palliative radiation was allowed. Ixabepilone was administered iv as a 3 hour infusion every 21 days. Initially, the dose was 50 mg/m(2) but this was lowered to 40 mg/m(2) shortly after the trial opened because of concerns about neurotoxicity. RESULTS: Sixty-two patients were registered however 2 were ineligible because they did not have recurrent or metastatic disease. For the 60 eligible patients, 22 had performance status of 0 and 38 performance status of 1. The estimated 6-month survival was 60% (95% CI 48%-72%) with a median survival of 7.2 months and an estimated time to treatment failure of 2.3 months. Out of 56 patients with measurable disease there were 5 confirmed partial responses for a confirmed response probability of 9% (95% CI 3%-20%) and 7 unconfirmed partial responses for an overall response probability of 21% (95% CI 12%-34%). Common toxicities were neutropenia/granulocytopenia, nausea and vomiting and neuropathy. There was one death, cause not determined but judged "possibly" related to treatment. CONCLUSION: Ixabepilone shows encouraging activity in patients with advanced pancreatic cancer and should be investigated further in this disease.
PURPOSE: The purpose of this Phase II multi-institutional study was to define the efficacy and toxicity of ixabepilone in patients with advance pancreatic adenocarcinoma. PATIENTS AND METHODS: Patients were required to have pancreatic adenocarcinoma and metastatic or recurrent disease that was not amenable to curative resection. Performance status was 0-1, and patients could not have had prior chemotherapy, or chemoradiation therapy for their advanced disease although prior local palliative radiation was allowed. Ixabepilone was administered iv as a 3 hour infusion every 21 days. Initially, the dose was 50 mg/m(2) but this was lowered to 40 mg/m(2) shortly after the trial opened because of concerns about neurotoxicity. RESULTS: Sixty-two patients were registered however 2 were ineligible because they did not have recurrent or metastatic disease. For the 60 eligible patients, 22 had performance status of 0 and 38 performance status of 1. The estimated 6-month survival was 60% (95% CI 48%-72%) with a median survival of 7.2 months and an estimated time to treatment failure of 2.3 months. Out of 56 patients with measurable disease there were 5 confirmed partial responses for a confirmed response probability of 9% (95% CI 3%-20%) and 7 unconfirmed partial responses for an overall response probability of 21% (95% CI 12%-34%). Common toxicities were neutropenia/granulocytopenia, nausea and vomiting and neuropathy. There was one death, cause not determined but judged "possibly" related to treatment. CONCLUSION:Ixabepilone shows encouraging activity in patients with advanced pancreatic cancer and should be investigated further in this disease.
Authors: F Y Lee; R Borzilleri; C R Fairchild; S H Kim; B H Long; C Reventos-Suarez; G D Vite; W C Rose; R A Kramer Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: John S Macdonald; Sheryl McCoy; Robert P Whitehead; Syma Iqbal; James L Wade; Jeffrey K Giguere; James L Abbruzzese Journal: Invest New Drugs Date: 2005-10 Impact factor: 3.850
Authors: E S Casper; M R Green; D P Kelsen; R T Heelan; T D Brown; C D Flombaum; B Trochanowski; P G Tarassoff Journal: Invest New Drugs Date: 1994 Impact factor: 3.850
Authors: Sridhar Mani; Hayley McDaid; Anne Hamilton; Howard Hochster; Marvin B Cohen; Dineo Khabelle; Tom Griffin; David E Lebwohl; Leonard Liebes; Franco Muggia; Susan Band Horwitz Journal: Clin Cancer Res Date: 2004-02-15 Impact factor: 12.531
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: Henry Q Xiong; Arthur Rosenberg; Albert LoBuglio; William Schmidt; Robert A Wolff; John Deutsch; Michael Needle; James L Abbruzzese Journal: J Clin Oncol Date: 2004-07-01 Impact factor: 44.544
Authors: Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Jason Konner; Rachel N Grisham; Jae Park; Owen A O'Connor; Gillian Cropp; Robert Johnson; Alison L Hannah; Martee L Hensley; Paul Sabbatini; Svetlana Mironov; Svetlana Miranov; Samuel Danishefsky; David Hyman; David R Spriggs; Jakob Dupont; Carol Aghajanian Journal: Invest New Drugs Date: 2011-11-10 Impact factor: 3.850
Authors: Hedy L Kindler; Peter K Tothy; Robert Wolff; Richard A McCormack; James L Abbruzzese; Sridhar Mani; Kurombi T Wade-Oliver; Everett E Vokes Journal: Invest New Drugs Date: 2005-10 Impact factor: 3.850
Authors: Robert P Whitehead; Sheryl McCoy; Saul E Rivkin; Howard M Gross; Marcel E Conrad; Gary C Doolittle; Robert A Wolff; J Wendall Goodwin; Shaker R Dakhil; James L Abbruzzese Journal: Invest New Drugs Date: 2006-11 Impact factor: 3.850
Authors: Pamela L Kunz; Aiwu R He; A Dimitrios Colevas; Michael J Pishvaian; Jimmy J Hwang; Pamela L Clemens; Marianne Messina; Remigiusz Kaleta; Fernanda Abrahao; Branimir I Sikic; John L Marshall Journal: Invest New Drugs Date: 2012-02-14 Impact factor: 3.850